What You Should Know:
– Unnatural Products, Inc. (UNP), a biotech company harnessing the power of AI and chemistry to design the next generation of targeted therapeutics, has secured $32M in Series A funding.
– Led by Merck Global Health Innovation Fund (MGHIF) and TechBio-focused ARTIS Ventures, the funding will help propel UNP’s innovative platform and expand its reach beyond oncology, tackling a wider range of medical challenges.
Macrocycles: Nature’s Key to Untapped Drug Targets
Macrocycles, cyclic molecules with unique properties, offer immense potential for tackling previously undruggable targets. They combine the potency and selectivity of antibodies with the oral bioavailability of small molecules, making them ideal for targeting intracellular proteins.
UNP’s AI-Fueled Platform: Revolutionizing Macrocycle Drug Discovery
UNP leverages a unique platform that combines parallel chemistry with AI-driven target identification and optimization. This enables the rapid development of synthetic macrocycles with the desirable drug-like properties of their natural counterparts.
“This is a pivotal moment for UNP,” says CEO and Co-Founder, Cameron Pye. “With this funding, we will accelerate the development of our platform and expand beyond oncology into new therapeutic areas. Macrocycles have the potential to revolutionize drug development, just like antibodies did in the early 2000s.”
